Priligy™ - Premature Ejaculation Drug

Priligy™ is an oral medication taken to combat the effects of premature ejaculation and is formerly known as Dapoxetine. The drug has been approved in some European countries such as Sweden and Finland and is increasingly in demand as a treatment for premature ejaculation. Although not yet approved for marketing authorisation in the United States, several other EU countries have approved the drug including Austria, Germany, Spain, Portugal and Italy.

Priligy (dapoxetine) has been extensively researched, evaluated and tested in various phase III clinical trials involving more than 5,000 men suffering from premature ejaculation, constituting one of the largest clinical trials to date for a drug to combat this condition. At Globalclinic.com we feel that this treatment has been fully verified as a safe and effective method of treating premature ejaculation and is therefore safe to offer to our customers.

Dapoxetine is classified as a SSRI (Selective Serotonin Reuptake Inhibitor) drug, which means it doesn’t need to be taken on a regular basis every day. It only needs to be taken an hour or two before sexual intercourse for the user to feel the benefits of the drug. Research suggests that serotonin plays a central role in the control and timing of ejaculation and an inhibitor such as Priligy delays the release of this hormone into the body and so delays the act of ejaculation.

Studies have revealed that more men suffer from PE than from Erectile Dysfunction and can strike men at any age. It is thought that a combination of physiological and psychological factors influences the mechanism of premature ejaculation, causing it to happen more quickly and with a reduced feeling of control. Using an inhibitor such as Priligy can help a man to regain that feeling of control and remove the negative personal impact the problem can have.

Our team of doctors has studied the research and test results of this product and feels that it is appropriate that we offer it as one of our website products. If you have any queries about this or any other treatment offered by Global-clinic.com, please contact us direct to discuss your requirements in complete confidence.

News:

PPD, Inc. today confirmed that Johnson & Johnson Pharmaceutical Research & Development have announced the completion of 3 additional Phase 3 studies using Priligy® for the treatment of P.E.

This new study increases the number of subjects in the Priligy clinical dataset to over 6,000 patients which provides an expanded safety database and confirmed efficacy. Johnson & Johnson Pharmaceutical Research & Development have announced their intention to review the new dataset with the U.S. F.D.A.

PPD is partnered with ALZA Corporation, a Janssen-Cilag affiliate, to develop Priligy, which is the first and only medication to be approved for the treatment of premature ejaculation.

The Food and Drug Administration did not approve Priligy in 2005 when it was first presented. Priligy has now been approved for the treatment of premature ejaculation in Finland, Sweden, Portugal, Austria, Germany, Italy and Spain. Additional regulatory filings are currently under review in the Middle East, Asia Pacific, North America and Latin America.

“Our hope is that these data will provide additional safety and efficacy information in support of the Priligy new drug application,” quoted Fred Eshelman, PPD’s chief executive officer. "We are pleased that our partner Janssen-Cilag continues to obtain clinical data for Priligy in pursuit of additional marketing approvals."

Priligy also known as Dapoxetine is now available to buy from Global Clinic www.globalclinic.com

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the safety and efficacy of Priligy® (dapoxetine), additional regulatory approvals and the value of PPD’s interest in Priligy, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks associated with the development and commercialization of drugs, including obtaining regulatory approvals; risks associated with and dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; competition in the development and commercialization of drugs to treat premature ejaculation; the ability to attract and retain key personnel; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; risks associated with acquisitions and investments, such as impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Published Jun. 10, 2009
Copyright © 2009 SYS-CON Media. All Rights Reserved.